Products - Parkinson's disease, tremor and dystonia | Topic | NICE

Showing 7 products

Date | Title

New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Unilateral and staged bilateral MRI-guided focused ultrasound thalamotomy for medication-refractory essential tremor
Status:
In development
Programme:
Interventional procedures guidance
Expected publication date:
17 December 2026
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Levodopa, carbidopa monohydrate and entacapone intestinal gel for treating the symptoms of advanced Parkinson’s disease [ID4005]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Deutetrabenazine for treating tardive dyskinesia [ID6550]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Levodopa inhaled for patients with Parkinson’s disease who experience ‘off’ episodes (motor response fluctuations) [TSID8778]
Status:
Topic prioritisation
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC